About CellPoint
CellPoint is a Healthcare company based in Leiden (Netherlands) founded in 2018 by Maarten Zandvliet, and was acquired by Galapagos in June 2022. CAR-T cell therapeutics are provided for hematological malignancies. CellPoint offers products and services including xCellit workflow system and Decentralized manufacturing platform. Its focus areas include Life Sciences, Immunotherapy, Adoptive Cell Therapy and T-Cell. Its legal entity is Galapagos NV.
Company details
CellPoint was founded in 2018 in Leiden, Netherlands, within the biotechnology sector focused on oncology. CAR-T cell-based therapeutics are developed to treat hematological malignancies, including acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and Hodgkins and non-Hodgkins lymphomas. Patient immune cells are retargeted at the point-of-care for personalized treatment. Key pipelines encompass CD-19 CAR-T in phase 2 clinical trials and BCMA CAR-T in the preclinical stage, among others.
- Headquarters Leiden, Netherlands
- Founders Maarten Zandvliet
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website cellpoint.bio
- Social LinkedIn
- Acquired by Galapagos (Jun 2022)
- Legal Name Galapagos Nv
Products & Services of CellPoint
CellPoint offers a comprehensive portfolio of products and services, including xCellit workflow system and Decentralized manufacturing platform.
Manages end-to-end workflow for cell therapy monitoring and operations.
Automates cell therapy production using closed systems for efficient treatment.
Investors in CellPoint
CellPoint has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GLPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Small molecule drugs for immunology and oncology are developed. | 1999 | glpg.com | Mechelen, Belgium |
Investor details for CellPoint
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CellPoint
1 people are tracked at CellPoint (1 in leadership).
| Name | Role | Group |
|---|---|---|
Maarten Zandvliet | Co-Founder | Leadership |
Complete people profiles for CellPoint
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CellPoint
2 dated milestones of CellPoint across 4 years, from founding to its latest funding, stage changes and deals.
- Founded CellPoint is founded.
- Exit Acquired by Galapagos.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cellpoint
Complete news archive for CellPoint
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellPoint
CellPoint was founded in 2018.
CellPoint is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
CellPoint was founded in 2018 in Leiden, Netherlands, within the biotechnology sector focused on oncology. CAR-T cell-based therapeutics are developed to treat hematological malignancies, including acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and Hodgkins and non-Hodgkins lymphomas. Patient immune cells are retargeted at the point-of-care for personalized treatment. Key pipelines encompass CD-19 CAR-T in phase 2 clinical trials and BCMA CAR-T in the preclinical stage, among others.
CellPoint offers xCellit workflow system and Decentralized manufacturing platform.
CellPoint has 1 investor. Key investors include GLPG.
CellPoint operates through Galapagos Nv.
Yes. CellPoint was acquired by Galapagos in June 2022.